Basis of Presentation - Narrative (Details) $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 13, 2019
element
|
Mar. 31, 2022
USD ($)
|
Jan. 31, 2022
USD ($)
|
Oct. 01, 2022
USD ($)
|
Apr. 02, 2022
USD ($)
|
Oct. 02, 2021
USD ($)
|
Oct. 01, 2022
USD ($)
|
Oct. 02, 2021
USD ($)
|
Dec. 31, 2021
USD ($)
|
Sep. 30, 2021
USD ($)
|
|
| Business Acquisition [Line Items] | ||||||||||
| Allowance for doubtful accounts | $ 3.4 | $ 3.4 | $ 3.2 | |||||||
| Bad debt expense | 0.3 | 0.4 | ||||||||
| Research and development expense | 12.0 | $ 11.3 | 36.8 | $ 31.9 | ||||||
| USDOT | AMPJ Award | ||||||||||
| Business Acquisition [Line Items] | ||||||||||
| USDOT grant receivable amount (up to) | $ 14.7 | |||||||||
| Portion of grant received | $ 2.1 | $ 5.2 | $ 7.4 | |||||||
| Revenue recognized included in contract liability balance | $ 6.0 | |||||||||
| Sold | Semiconductor Test Business | Test Systems | ||||||||||
| Business Acquisition [Line Items] | ||||||||||
| Number of elements for contingent earnouts | element | 2 | |||||||||
| Earnout proceeds received | $ 11.3 | $ 10.7 | ||||||||
| X | ||||||||||
- Definition Disposal Group, Including Discontinued Operation, Contingent Consideration Received No definition available.
|
| X | ||||||||||
- Definition Grant Recognized No definition available.
|
| X | ||||||||||
- Definition Number Of Elements For Contingent Earn-Outs No definition available.
|
| X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of cash inflow from the collection of receivables classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (reversal of expense) for expected credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|